# AeroVironment Inc. (AVAV) — Financial Analysis

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/AVAV/thesis · /stocks/AVAV/memo

## Financial Snapshot

---
step: 04
title: Financial Quality (incl. Adversarial Sweep)
ticker: AVAV
source: coverage-next-full
date: 2026-05-28
---

### AVAV — Step 04: Financial Quality & Adversarial Sweep

#### TL;DR
Financial quality is **MIXED — leaning cautious through FY26**. Positives: revenue growth structurally accelerating (+14.5% FY25 standalone → +130% FY26 inorganic via BlueHalo), $1.1B record funded backlog (+52% YoY) [S3], non-GAAP EBITDA tracking guidance. Concerns: (1) Three goodwill impairments in 4 years (FY23 Tomahawk/Telerob $-180M; FY26 Q3 BADGER Space $-151M), (2) BlueHalo had pre-acquisition material weaknesses in internal controls — *acquirer explicitly disclosed this in 10-K* [S1], (3) operating cash flow $(1.3)M FY25 and $(124)M Q1 FY26 reflects working-capital absorption from Switchblade ramp + integration, (4) Q3 FY26 revenue miss vs. consensus and FY26 guidance cut, (5) ~$175M annual intangible amortization will suppress GAAP profitability through FY28+. **Adversarial sweep result: No active short reports, no SEC investigation, no material litigation disclosed beyond ordinary defense-contractor cases. The class-action securities/employment suit filed 2021-08 is the only flagged item.** Net: financial quality is real but obscured by acquisition accounting; investors must judge on non-GAAP through FY27.

#### 1. Statement-Quality Adjustments

##### GAAP-to-Economic earnings bridge (annualized FY26 mid)

| Adjustment | $M | Rationale |
|------------|-----|-----------|
| GAAP Net Income (mgmt mid) | (210) | $(218)-(201) guide [S3] |
| Add: Intangible amortization (after-tax) | +140 | $175M pre-tax × 80% (after-tax) — non-cash, will decline FY27 onward [Judgment] |
| Add: Q3 Goodwill impairment (after-tax) | +120 | One-time BADGER SCAR $151M pre-tax — non-recurring [S3] |
| Add: Transaction & integration costs (after-tax) | +25 | One-time BlueHalo integration [Estimate] |
| Less: SBC reversal | (32) | $40M pre-tax × 80% — real economic cost [Judgment] |
| **Adjusted Economic Net Income** | **~43** | Translation: AVAV's underlying earnings power FY26 ~$43M → ~$1.45/sh × 49.7M shares ≈ in-line with non-GAAP EPS mid $2.93 if amort fully excluded |

**Implication:** Don't take GAAP at face value through FY27. Non-GAAP EBITDA + adjusted cash earnings are the meaningful read.

##### Quality red flags vs. quality positives

| Quality Indicator | Reading | Notes |
|-------------------|---------|-------|
| Goodwill impairments | **3 events in 4 years** | FY23 ~$180M (Tomahawk/Telerob legacy) + FY26 Q3 $151M (BADGER) [S1][S3]. Pattern of overpaying for M&A targets relative to subsequent execution. |
| Acquired-entity internal controls | **Disclosed material weakness on BlueHalo** | "Prior to our acquisition of BlueHalo, BlueHalo was not a U.S. public reporting company. The obligations associated with integrating into a public company, including to remediate BlueHalo's material weaknesses in internal control over financial reporting…" [S1] |
| OCF vs. Net Income | **OCF lags by ~$45M FY24-25** | Working-capital absorption from Switchblade inventory + Ukraine receivables timing [S6] |
| SBC % of revenue | 2.6% FY25; ~2% FY26 run | Within defense industry norm [S6] |
| Receivables/sales ratio | ~30% (DSO ~110 days) | Defense industry norm given gov contracting payment cycles [S6] |
| Goodwill / Total Assets | ~23% FY25 (~$256M / $1.1B); will spike materially post-BlueHalo | Post-BH likely 50%+ → high impairment-risk balance sheet [Estimate] |
| Revenue growth quality | Mostly real, organic + acquired | FY25 +14.5% organic real; FY26 mostly BlueHalo |
| Guidance reliability | **Recently cut at Q3 FY26** | $1.95-2.0B → $1.85-1.95B (~$75M mid-point cut) [S3]. Confidence in mgmt forecasting credibility is currently degraded. |
| Non-GAAP definitions | Reasonable add-backs (amort, SBC, transaction costs); no aggressive recurring "one-time" items | Defensible [Judgment] |
| Audit firm | Ernst & Young | Per DEF 14A [S5] |

#### 2. Adversarial Research Sweep

##### Short reports / investigations / lawsuits

| Source | Result | Notes |
|--------|--------|-------|
| **Active short reports** | NONE FOUND | No Hindenburg / Muddy Waters / Kerrisdale / Spruce Point on AVAV as of 2026-05-28 [S7] |
| **SEC investigations / enforcement** | NONE DISCLOSED | No 10-K disclosure; no Wells Notice; no formal SEC comment letter outstanding [S1] |
| **DOJ / FCPA / ITAR violations** | NONE DISCLOSED | Routine compliance certifications in 10-K; no flagged investigations [S1] |
| **Government contract suspensions** | NONE | AVAV remains active vendor on all material programs |
| **Material litigation** | One class action | "2021-08-09 class action filed by former employee — ongoing securities/employment litigation" per 10-K Item 3 [S1]. Magnitude not material as disclosed (would be quantified if material). |
| **Whistleblower-driven inquiries** | NONE FOUND | [S7] |
| **Form 144 / unusual insider activity** | Routine cadence | Mostly post-merger insider initial-3 filings + 10b5-1 plan sales [S5] |
| **Auditor changes** | NONE recent | EY consistent [S5] |
| **Restatements** | NONE | No restatements in FY18-FY25 [S1] |

##### Specific adversarial angles worth pre-empting

1. **"3 goodwill impairments in 4 years means M&A discipline is poor"** — fair concern. BUT: Arcturus (FY21) has produced JUMP 20 with strong PoR economics, so not all M&A has failed. Tomahawk and BADGER (BlueHalo space program) are the specific failures. Watch BlueHalo cyber/EW for similar risk. [Judgment]

2. **"BlueHalo material weakness = AVAV is bringing in a not-public-ready entity"** — explicit 10-K disclosure makes this a known risk, not a surprise. Remediation timeline typically 18-24 months. The audit firm-of-record (EY) accepted the merger without qualification, so the remediation plan is presumably credible. [Judgment]

3. **"Q3 FY26 miss + guidance cut suggests organic deceleration is being masked by BlueHalo"** — partially true. Organic Q3 FY26 ~$232M vs. $167.6M PY = +38% organic, so the legacy AV business is *not* decelerating. But BlueHalo's Q3 contribution ($176M) was *below* the implied Q1-Q2 run-rate, suggesting BlueHalo ramp choppier than projected. [Judgment, S3]

4. **"Arlington Capital's 39.5% block = secondary supply overhang"** — real. Lock-up typically 6-12 months; Arlington will sell over 12-24 months as PE fund-of-funds distribution. Stock-price headwind structural for that period. [Judgment, A16]

5. **"BADGER SCAR stop-work is a leading indicator for other BlueHalo program cuts"** — bear concern, hard to disprove. Watch FY27 Q1-Q2 disclosures for incremental Space program awards or cuts. [Judgment]

##### Forensic checks
- **Days Sales Outstanding (DSO):** ~110 days (Receivables $250M / Daily revenue $2.25M FY25). Defense industry norm given gov payment cycles. No anomaly [S6, Calculation]
- **Inventory days:** Materially elevated FY24-Q1 FY26 — Switchblade production-ahead-of-demand pattern. Watch for write-down risk if demand softens [S6]
- **Goodwill to equity:** Materially elevated post-BlueHalo (~$2-3B goodwill / book equity to be confirmed in FY26 10-K). High impairment-test sensitivity [Estimate]
- **R&D expensing vs. capitalization:** R&D appears properly expensed; no aggressive capitalization detected [S1]
- **Customer-funded R&D as revenue:** Disclosed separately in segment reporting; no commingling apparent [S1]

#### 3. Financial Quality Score (1-5 scale)

| Dimension | Score | Notes |
|-----------|-------|-------|
| Revenue recognition quality | 4/5 | ASC 606 properly applied; mix of fixed-price + CPFF + T&M handled cleanly |
| Cash flow vs. earnings | 3/5 | OCF lags meaningfully due to working capital — improvement requires backlog burn cadence |
| Balance sheet conservatism | 2/5 | High goodwill % of assets; concentrated post-BH; impairment risk elevated |
| Disclosure transparency | 4/5 | Segment reporting clear; non-GAAP reconciliations clean; material weakness disclosed |
| Management guidance reliability | 2/5 | Recent Q3 FY26 cut degrades confidence |
| Auditor / ICFR | 3/5 | EY clean opinion + AVAV side; BlueHalo side has disclosed material weakness pending remediation |
| **Composite** | **3/5** | Mixed quality — improving once amortization tail fully runs through and remediation completes |

#### 4. Implications for Thesis
- **Use non-GAAP EBITDA + adjusted economic earnings for valuation through FY27** — GAAP will mislead. [Step 14 / `/complete-coverage`]
- **Apply impairment-risk discount** to AVAV's terminal valuation given track record (3 impairments in 4 years). [Step 14]
- **Bear case must explicitly stress test additional BlueHalo program cuts** — BADGER may not be the last. [Step 15]
- **Working capital build is real but acceptable** given backlog growth supports demand. Watch for inventory write-down if Switchblade demand softens (unlikely near-term).
- **Material weakness remediation timeline (18-24 months)** is a watch-item but not a thesis-breaker — disclosed and being managed.

#### 5. Tables — Multi-year Financial Snapshot

##### Annual Income Statement Highlights ($M)

| FY | Revenue | YoY% | GP | GP% | Op Inc | Op% | NI | Diluted EPS | Backlog |
|----|---------|------|----|----|--------|-----|----|-------------|---------|
| FY20 | ~367 | +17% | 153 | ~42% | 47 | 13% | 41 | $1.71 | n/a |
| FY21 | ~395 | +8% | 165 | ~42% | 43 | 11% | 23 | $0.96 | n/a |
| FY22 | ~446 | +13% | 141 | ~32% | (10) | (2%) | (4) | $(0.17) | n/a |
| FY23 | ~540 | +21% | 173 | ~32% | (179) | (33%) | (176) | $(7.04) | n/a |
| FY24 | 716.7 | +33% | 284 | 39.6% | 72 | 10.0% | 60 | $2.18 | n/a |
| FY25 | 820.6 | +14.5% | 319 | 38.8% | 41 | 5.0% | 44 | $1.55 | $727M |
| FY26E | 1,900 | +132% | n/a | n/a | (290)G | (15%) | (210) | $(4.27)G / $2.93N | $1.1B+ |

G=GAAP, N=Non-GAAP. [Source: S1, S3, S6]

##### Annual Cash Flow ($M)

| FY | OCF | CapEx | FCF | M&A spend |
|----|-----|-------|-----|-----------|
| FY20 | 25 | 11 | 14 | small |
| FY21 | 87 | 11 | 75 | ~(400) Arcturus |
| FY22 | (10) | 22 | (32) | small |
| FY23 | 11 | 15 | (4) | small |
| FY24 | 15 | 23 | (8) | ~(120) Tomahawk |
| FY25 | (1) | 23 | (24) | 0 (BH all-stock) |
| FY26 Q1 | (124) | n/a | n/a | BH close costs |

[S6][S1]

#### 6. Open Questions
1. FY26 10-K goodwill/intangible balance — what is true post-BlueHalo carrying value?
2. BlueHalo segment-level profitability — has it been disclosed in Q1-Q3 FY26 10-Qs? (currently aggregate only)
3. Working-capital normalization trajectory — when does OCF turn positive?
4. Material weakness remediation status — first disclosure in FY26 10-K (June 2026)
5. Any additional Space programs at SCAR stop-work risk?

#### Source Index

| Source Tag | Document / URL | Section | Date | Notes |
|------------|----------------|---------|------|-------|
| [S1] | AVAV 10-K FY25 (accession 0001558370-25-008838) | Item 1A Risk Factors; Item 7 MD&A; Item 9A ICFR | 2025-06-25 | Material weakness; goodwill impairment history |
| [S3] | AVAV Q3 FY26 8-K + PR (accession 0001104659-26-025841) | Income statement; non-GAAP recon; impairment disclosure | 2026-03-10 | $151M Space goodwill impairment; FY26 guide cut |
| [S5] | AVAV DEF 14A 2025 (accession 0001104659-25-077059) | Auditor; comp design | 2025-08-13 | EY; PSU/RSU structure |
| [S6] | AVAV_financials/xbrl/xbrl_summary.md | OCF/CapEx/SBC; quarterly P&L | 2026-05-28 | Multi-year cash flow + working-capital trend |
| [S7] | Tavily web search 2026-05-28 + AVAV_financials/other/consensus.md | Short-seller / litigation check | 2026-05-28 | No active short reports found |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/AVAV/fundamental

## Navigation

- Overview: /stocks/AVAV
- Financials (this page): /stocks/AVAV/financials
- Thesis: /stocks/AVAV/thesis
- Investment Memo: /stocks/AVAV/memo
- Coverage universe: /stocks